Impact of the duration of corticosteroid treatment for postoperative acute lung injury following lung cancer surgery.

J Thorac Dis

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Published: January 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Acute lung injury (ALI) is one of the most serious pulmonary complications following lung resection. Despite the known beneficial effects of corticosteroid treatment for postoperative ALI, limited data are available regarding corticosteroid treatment duration. This study aimed to evaluate the beneficial effects of a short-course corticosteroid in patients with postoperative ALI following lung resection surgery for lung cancer.

Methods: This retrospective observational study included 91 patients who were treated with corticosteroids for postoperative ALI among 7,317 patients who underwent lung resection surgery for lung cancer between January 2017 and March 2021. Patients were divided into two groups, short (≤14 days, n=31) and long (≥15 days, n=60) courses, on the basis of corticosteroid treatment duration.

Results: While similar baseline characteristics were observed between the two groups, the short-course group had a higher corticosteroid loading dose than the long-course group; however, the cumulative dose in the first 7 days was not different between the two groups. Overall, in-hospital mortality rates were 3.2% and 26.7% in the short- and long-course groups, respectively (P=0.01). Moreover, the long-course group had higher additional intensive care unit (ICU) admission (32.3% 60.0%, P=0.02) and persistent air leakage (0% 13.3%, P=0.09). In the logistic regression analysis, corticosteroid treatment duration was marginally associated with in-hospital mortality [adjusted odds ratio (OR), 9.03; 95% confidence interval (CI): 0.96-84.9, P=0.054].

Conclusions: Short-course corticosteroid treatment was associated with a lower rate of surgical site complications, additional ICU admission, and in-hospital mortality, which suggests the necessity of efforts for reducing the total duration by weighing the benefits and adverse effects of corticosteroid treatment for postoperative ALI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833561PMC
http://dx.doi.org/10.21037/jtd-24-1295DOI Listing

Publication Analysis

Top Keywords

corticosteroid treatment
28
postoperative ali
16
treatment postoperative
12
lung resection
12
in-hospital mortality
12
corticosteroid
9
lung
8
acute lung
8
lung injury
8
lung cancer
8

Similar Publications

[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)].

Bull Cancer

September 2025

Service d'hématologie, département d'oncologie, hôpitaux universitaire de Genève (HUG), faculté de médecine, université de Genève, Genève, Suisse. Electronic address:

Acute graft-versus-host disease (GVHDa) is one of the leading causes of morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT) patients. While the first-line consensus treatment has been based on systemic corticosteroid therapy for many years, ruxolitinib has recently been approved and has become the standard second-line treatment. Nevertheless, the effectiveness of ruxolitinib remains limited to 40 % of cortico-resistant patients, raising the crucial question of selecting a third-line treatment.

View Article and Find Full Text PDF

Prototheca wickerhamii Causing Toe Infection Presenting Initially as Gouty Arthritis: A Rare Case Report.

Int J Infect Dis

September 2025

Department of Laboratory Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China. Electronic address:

Prototheca, a genus of opportunistic pathogenic microalgae, can cause protothecosis in humans and animals, manifesting as cutaneous lesions or disseminated/systemic infections. This report describes a rare case of Prototheca wickerhamii toe infection in a 78-year-old Chinese male, presenting initially as gouty arthritis. The patient, who worked in fish farming with frequent water exposure, had a history of herpes zoster and hypertension.

View Article and Find Full Text PDF

Osteoarthritis year in review 2025: Epidemiology and Therapy.

Osteoarthritis Cartilage

September 2025

Clinical Epidemiology Unit, Orthopaedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address:

Aim: To summarise key epidemiological and therapeutic research on osteoarthritis (OA) published between April 2024 and March 2025.

Methods: A narrative review was conducted using the MEDLINE database, focusing on English-language studies involving human participants published between April 1, 2024 and March 31, 2025. Eligible studies included observational longitudinal studies, systematic reviews, meta-analyses, and phase II-IV randomised controlled trials (RCTs) examining OA treatment and epidemiology.

View Article and Find Full Text PDF

Immune-mediated necrotizing myopathy: an emerging disorder.

Neurologia (Engl Ed)

September 2025

Unidad de ELA-Neuromuscular, Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, Spain; IiSGM, Instituto de Investigación Sanitaria Gregorio Marañón.

Objectives: To describe the main features and the clinical management of a cohort of patients with immune-mediated necrotizing myopathy (IMNM).

Methods: We conducted an observational, monocentric, retrospective study of IMNM patients diagnosed in the Neuromuscular Unit of a tertiary hospital in Madrid (Spain) between 2013 and 2021.

Results: Sixteen IMNM cases were diagnosed, with a median age of 71.

View Article and Find Full Text PDF

Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial.

Lancet Rheumatol

September 2025

National Institute for Health and Care Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. Electronic address:

Background: The optimal treatment strategy in early psoriatic arthritis remains unknown. We aimed to assess whether the combination of methotrexate and golimumab plus corticosteroids is superior to methotrexate plus corticosteroids in reducing disease activity in early, untreated psoriatic arthritis.

Methods: We did a double-blind, randomised, placebo-controlled, parallel-group, single-centre study in adults with treatment-naïve active psoriatic arthritis.

View Article and Find Full Text PDF